Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders
Authors
Keywords
-
Journal
Expert Opinion on Drug Metabolism & Toxicology
Volume -, Issue -, Pages 1-16
Publisher
Informa UK Limited
Online
2020-09-09
DOI
10.1080/17425255.2020.1817380
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial
- (2020) W. Joseph Herring et al. Alzheimers & Dementia
- Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder
- (2020) Yves Dauvilliers et al. ANNALS OF NEUROLOGY
- Lemborexant: First Approval
- (2020) Lesley J. Scott DRUGS
- Safety of Lemborexant Versus Placebo and Zolpidem: Effects on Auditory Awakening Threshold, Postural Stability, and Cognitive Performance in Healthy Older Subjects in the Middle of the Night and Upon Morning Awakening
- (2020) Patricia Murphy et al. Journal of Clinical Sleep Medicine
- Repurposing the dual orexin receptor antagonist suvorexant for the treatment of opioid use disorder: why sleep on this any longer?
- (2020) Morgan H. James et al. NEUROPSYCHOPHARMACOLOGY
- 164 Pooled Analyses of Patient-Reported Sleep Onset and Maintenance from Two Phase 3 Studies of Lemborexant
- (2020) Russell Rosenberg et al. CNS SPECTRUMS
- Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder
- (2020) Gary Zammit et al. NEUROLOGY
- The dual orexin receptor antagonist daridorexant does not affect the pharmacokinetics of the BCRP substrate rosuvastatin
- (2020) Isabelle Zenklusen et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia
- (2019) Sander Brooks et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Effect of suvorexant on nighttime blood pressure in hypertensive patients with insomnia: The SUPER‐1 study
- (2019) Kazuomi Kario et al. Journal of Clinical Hypertension
- Investigating the Metabolism of ACT-541468, Utilizing a Microtracer and Accelerator Mass Spectrometry in The First-in-Humans Trial
- (2019) Clemens Muehlan et al. CURRENT DRUG METABOLISM
- Use of Suvorexant for Sleep Regulation in an Adolescent with Early-Onset Bipolar Disorder
- (2019) Diana I. Prieto et al. JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
- 0373 Effects of Suvorexant on Sleep in Fibromyalgia
- (2019) Gail Koshorek et al. SLEEP
- Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration
- (2019) Clemens Muehlan et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update
- (2019) Sue Wilson et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Obstructive sleep apnea treatment in adults
- (2019) Hong‐Po Chang et al. KAOHSIUNG JOURNAL OF MEDICAL SCIENCES
- The assessment and management of insomnia: an update
- (2019) Andrew D. Krystal et al. World Psychiatry
- The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder
- (2019) Kasper Recourt et al. Translational Psychiatry
- Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration
- (2019) Clemens Muehlan et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Dual orexin receptor antagonists increase sleep and cataplexy in wild type mice
- (2019) Carrie E Mahoney et al. SLEEP
- Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: 12-month results from sunrise-2
- (2019) J. Yardley et al. SLEEP MEDICINE
- Co-Morbid Insomnia and Sleep Apnea (COMISA): Prevalence, Consequences, Methodological Considerations, and Recent Randomized Controlled Trials
- (2019) Alexander Sweetman et al. Brain Sciences
- Accelerated Development of the Dual Orexin Receptor Antagonist ACT-541468: Integration of a Microtracer in a First-in-Human Study
- (2018) Clemens Muehlan et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity
- (2018) Peter De Boer et al. JOURNAL OF PSYCHOPHARMACOLOGY
- The Orexin/Receptor System: Molecular Mechanism and Therapeutic Potential for Neurological Diseases
- (2018) Chunmei Wang et al. Frontiers in Molecular Neuroscience
- Multiple daytime administration of the selective orexin-2 receptor antagonist JNJ-42847922 induces somnolence in healthy subjects without residual central effects
- (2018) Peter D van der Ark et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Interaction potential of the dual orexin receptor antagonist ACT-541468 with CYP3A4 and food: results from two interaction studies
- (2018) Marie-Laure Boof et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers
- (2018) Annemiek Vermeeren et al. SLEEP
- Sleep hygiene education as a treatment of insomnia: a systematic review and meta-analysis
- (2017) Ka-Fai Chung et al. FAMILY PRACTICE
- Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline
- (2017) Michael J. Sateia et al. Journal of Clinical Sleep Medicine
- Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study
- (2017) Patricia Murphy et al. Journal of Clinical Sleep Medicine
- The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468
- (2017) Alexander Treiber et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- European guideline for the diagnosis and treatment of insomnia
- (2017) Dieter Riemann et al. JOURNAL OF SLEEP RESEARCH
- Efficacy and safety of almorexant in adult chronic insomnia: a randomized placebo-controlled trial with an active reference
- (2017) Jed Black et al. SLEEP MEDICINE
- Benzodiazepines and Z-Drugs: An Updated Review of Major Adverse Outcomes Reported on in Epidemiologic Research
- (2017) Jaden Brandt et al. Drugs in research & development
- Postoperative delirium after pharyngolaryngectomy with esophagectomy: a role for ramelteon and suvorexant
- (2017) Eisuke Booka et al. Esophagus
- Psychological and Behavioral Interventions for Managing Insomnia Disorder: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians
- (2016) Michelle Brasure et al. ANNALS OF INTERNAL MEDICINE
- Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians
- (2016) Amir Qaseem et al. ANNALS OF INTERNAL MEDICINE
- Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials
- (2016) W. Joseph Herring et al. BIOLOGICAL PSYCHIATRY
- Insomnia and the risk of depression: a meta-analysis of prospective cohort studies
- (2016) Liqing Li et al. BMC Psychiatry
- Concentration-Response Modeling of ECG Data From Early-Phase Clinical Studies as an Alternative Clinical and Regulatory Approach to Assessing QT Risk - Experience From the Development Program of Lemborexant
- (2016) Patricia J. Murphy et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea
- (2016) Hong Sun et al. Journal of Clinical Sleep Medicine
- On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly
- (2016) Annemiek Vermeeren et al. PSYCHOPHARMACOLOGY
- Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data
- (2016) Ellen Snyder et al. SLEEP MEDICINE
- In vitroandin vivocharacterisation of the metabolism and disposition of suvorexant in humans
- (2016) Donghui Cui et al. XENOBIOTICA
- The Pathophysiology of Insomnia
- (2015) Jessica C. Levenson et al. CHEST
- The neurobiology, investigation, and treatment of chronic insomnia
- (2015) Dieter Riemann et al. LANCET NEUROLOGY
- Insomnia Disorder
- (2015) John W. Winkelman NEW ENGLAND JOURNAL OF MEDICINE
- Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease
- (2015) Hong Sun et al. RESPIRATORY MEDICINE
- On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers
- (2015) Annemiek Vermeeren et al. SLEEP
- On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers
- (2015) Annemiek Vermeeren et al. SLEEP
- Hypnotics in Insomnia: The Experience of Zolpidem
- (2014) James MacFarlane et al. CLINICAL THERAPEUTICS
- Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
- (2014) L. Citrome INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial
- (2014) David Michelson et al. LANCET NEUROLOGY
- Orexin receptor antagonists: a new treatment for insomnia?
- (2014) Dieter Riemann et al. LANCET NEUROLOGY
- Motivational activation: a unifying hypothesis of orexin/hypocretin function
- (2014) Stephen V Mahler et al. NATURE NEUROSCIENCE
- Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis
- (2014) Akira Kuriyama et al. SLEEP MEDICINE
- Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 receptor antagonism
- (2014) Christine Dugovic et al. Frontiers in Neuroscience
- Discovery and Characterization of ACT-335827, an Orally Available, Brain Penetrant Orexin Receptor Type 1 Selective Antagonist
- (2013) Michel A. Steiner et al. ChemMedChem
- Association Between Insomnia Symptoms and Mortality
- (2013) Yanping Li et al. CIRCULATION
- Orexin (Hypocretin) Receptor Agonists and Antagonists for Treatment of Sleep Disorders
- (2013) Michihiro Mieda et al. CNS DRUGS
- Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand?
- (2013) Daniel Hoyer et al. NEUROPEPTIDES
- Orexin Receptor Antagonism, a New Sleep-Enabling Paradigm: A Proof-of-Concept Clinical Trial
- (2012) P Hoever et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Orexin receptor antagonism for treatment of insomnia: A randomized clinical trial of suvorexant
- (2012) W. J. Herring et al. NEUROLOGY
- Dual Hypocretin Receptor Antagonism Is More Effective for Sleep Promotion than Antagonism of Either Receptor Alone
- (2012) Stephen R. Morairty et al. PLoS One
- Orexin neurons as conditional glucosensors: paradoxical regulation of sugar sensing by intracellular fuels
- (2011) Anne Venner et al. JOURNAL OF PHYSIOLOGY-LONDON
- Activation of Central Orexin/Hypocretin Neurons by Dietary Amino Acids
- (2011) Mahesh M. Karnani et al. NEURON
- Sleep and the Brain
- (2011) Ian M. Colrain NEUROPSYCHOLOGY REVIEW
- (Mis)perception of sleep in insomnia: A puzzle and a resolution.
- (2011) Allison G. Harvey et al. PSYCHOLOGICAL BULLETIN
- Nighttime Insomnia Symptoms and Perceived Health in the America Insomnia Survey (AIS)
- (2011) James K. Walsh et al. SLEEP
- Next-Day Effects of Ramelteon (8 mg), Zopiclone (7.5 mg), and Placebo on Highway Driving Performance, Memory Functioning, Psychomotor Performance, and Mood in Healthy Adult Subjects
- (2011) Monique A.J. Mets et al. SLEEP
- Orexin Receptor Antagonism, a New Sleep-Promoting Paradigm: An Ascending Single-Dose Study With Almorexant
- (2010) P Hoever et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Discovery of the Dual Orexin Receptor Antagonist [(7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the Treatment of Insomnia
- (2010) Christopher D. Cox et al. JOURNAL OF MEDICINAL CHEMISTRY
- Prevalence of insomnia and sleep characteristics in the general population of Spain
- (2010) Maurice M. Ohayon et al. SLEEP MEDICINE
- Orexin receptor subtype activation and locomotor behaviour in the rat
- (2009) W. K. Samson et al. Acta Physiologica
- Efficacy and Safety of Doxepin 1 mg, 3 mg, and 6 mg in Elderly Patients With Primary Insomnia
- (2009) Martin Scharf et al. JOURNAL OF CLINICAL PSYCHIATRY
- Blockade of Orexin-1 Receptors Attenuates Orexin-2 Receptor Antagonism-Induced Sleep Promotion in the Rat
- (2009) C. Dugovic et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- The hyperarousal model of insomnia: A review of the concept and its evidence
- (2009) Dieter Riemann et al. SLEEP MEDICINE REVIEWS
- Ramelteon
- (2008) Dene Simpson et al. DRUGS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now